Mei Ri Jing Ji Xin Wen·2025-12-31 07:48Group 1 - The recent inclusion of long-acting growth hormone in the national medical insurance directory is expected to significantly reduce treatment costs for families, with prices dropping from approximately 4000-5000 yuan per month to around 2000 yuan after January 2026 [1][2] - Two long-acting growth hormone products, namely Yipei and Jinsai, have been included in the national medical insurance directory, with Yipei's price reduced by about 53% from 1798 yuan to 853.2 yuan, and Jinsai's price reduced by approximately 75% from 3500 yuan to around 900 yuan [2][3] - The annual treatment cost for patients with growth hormone deficiency is projected to decrease from about 120,000 yuan to 30,000 yuan after the price reduction, with further reductions possible through local insurance reimbursements [2][3] Group 2 - The growth hormone market in China has rapidly expanded, with the market size increasing from 4 billion yuan in 2018 to 12 billion yuan in 2022, making China the largest market globally for growth hormone [7][8] - The competitive landscape is evolving, with multiple companies, including Jinsai and Yipei, as well as new entrants like Anke Bio and Tianjing Bio, actively developing long-acting growth hormone products [8][9] - The approval of international long-acting growth hormone products, such as Novo Nordisk's product, is expected to intensify competition in the domestic market [8][9]